Enasidenib Approved for AML, but Best Uses Unclear

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-nb2017-117
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

New PrEP Formulation Approved…but Only for Some

The Lancet HIV
EpidemiologyInfectious DiseasesImmunologyVirology
2019English

Innovations in Total Knee Arthroplasty: Improved Technical Precision, but Unclear Clinical Benefits

Orthopedics
SurgeryOrthopedicsSports Medicine
2016English

Cost Effectiveness in Screening for Down's Syndrome Still Unclear

BMJ
2002English

Breast Is Best, but Not in My Back-Yard

Trends in Molecular Medicine
Molecular MedicineMolecular Biology
2015English

Eq.(1) Seems Unclear

2019English

CD34+ Megakaryoblastic Leukaemic Cells Are CD38−, but CD61+ and Glycophorin A+: Improved Criteria for Diagnosis of AML-M7?

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
1997English

Avastin Approved for Some Cervical Cancers

Cancer Discovery
Oncology
2014English

Cemiplimab Approved for Treatment of CSCC

Cancer Discovery
Oncology
2018English

Unclear Intentions: Eavesdropping in Microbial and Plant Systems

Frontiers in Ecology and Evolution
EvolutionEcologySystematicsBehavior
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy